BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 27 found
  Current Search:  impetigo: 27     

HTML
100%
The value of Tzanck smear test in diagnosis of erosive, vesicular, bullous, and pustular skin lesions
Durdu M et al.

- Tzanck smear was performed in a total of 400 patients with moist skin lesions.

The sensitivities of multinucleated giant cells and acantholytic cells in herpetic infections, dyskeratotic acantholytic cells and cocci in...

MDLinx:  Nov 28 2008 2:30AM
Matching: impetigo
Find similar documents
HTML
100%
Spotlight on Retapamulin in Impetigo and Other Uncomplicated Superficial Skin Infections
Yang LPH et al.

- The introduction of topical retapamulin 1% ointment extends the treatment options available in the management of impetigo and uncomplicated secondarily infected traumatic lesions.

Spotlight on Retapamulin in ...

MDLinx:  Nov 19 2008 5:41PM
Matching: impetigo
Find similar documents
HTML
100%
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
- (NewsRx.com) -- Medimetriks Pharmaceuticals announced that the Company entered into a licensing agreement with Perrigo Company (NASDAQ:PRGO) for the U.S.

marketing rights to Centany(R) Ointment and two prescription keratolytic brands.

Macro World Investor:  Nov 7 2008 1:45AM
Matching: impetigo
Find similar documents
HTML
100%
Perrigo Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Pharmaceuticals has announced that the company has entered into a licensing agreement with Perrigo Company for the U.S.

marketing rights to Centany(R) Ointment and two prescription keratolytic brands.

Patented through 2018,...

PharmaceuticalProcessing:  Oct 29 2008 10:25AM
Matching: impetigo
Find similar documents
HTML
100%
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.

28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...

TickerTech.com:  Oct 28 2008 10:20PM
Matching: impetigo
Find similar documents
HTML
100%
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.

28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...

SmartBrief:  Oct 28 2008 8:12PM
Matching: impetigo
Find similar documents
HTML
100%
Medimetriks announces agreement to market treatments for impetigo
_ Medimetriks announces agreement to market treatments for impetigo.
Drug Store News:  Oct 28 2008 8:02PM
Matching: impetigo
Find similar documents
HTML
100%
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product PortfolioFAIRFIELD, N.J., Oct.

28 (HSMN NewsFeed) -- Medimetriks Pharmaceuticals announced today that the Company entered into a...

Healthcare Sales & Marketing Network:  Oct 28 2008 8:02PM
Matching: impetigo
Find similar documents
HTML
100%
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.

28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...

Pharma Live:  Oct 28 2008 1:05PM
Matching: impetigo
Find similar documents
HTML
100%
Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
Medimetriks Adds Centany(R) (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio FAIRFIELD, N.J., Oct.

28 /PRNewswire/ -- Medimetriks Pharmaceuticals announced today that the Company entered into a...

Calibre Macro World:  Oct 28 2008 12:39PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

KRON4:  Oct 27 2008 1:07AM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

KLFY:  Oct 26 2008 10:42PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Montana's News Station:  Oct 26 2008 8:43PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

KSLA:  Oct 26 2008 6:02PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 20
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Interest!ALERT:  Oct 26 2008 5:40PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Business Journal of Milwaukee:  Oct 26 2008 4:57PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Forbes.com:  Oct 26 2008 4:48PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Columbus Business First:  Oct 26 2008 4:40PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Nashville Business Journal:  Oct 26 2008 4:35PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Atlanta Business Chronicle:  Oct 26 2008 4:34PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Portland Business Journal:  Oct 26 2008 4:34PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

The Business Journal Phoenix:  Oct 26 2008 4:33PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

San Francisco Business Times:  Oct 26 2008 4:30PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

San Antonio Business Journal:  Oct 26 2008 4:29PM
Matching: impetigo
Find similar documents
HTML
100%
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/I
- Once-a-Day Radezolid Clinically and Microbiologically As Effective As Twice-a-Day Linezolid When Used to Treat a Variety of uSSSIs - NEW HAVEN, Conn., Oct.

26 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc.

('Rib-X' or the 'Company'), a...

Cincinnati Business Journal:  Oct 26 2008 4:28PM
Matching: impetigo
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2008 - BioPortfolio Limited.